The Chemours Company (NYSE:CC) Shares Purchased by New York State Common Retirement Fund

New York State Common Retirement Fund grew its position in shares of The Chemours Company (NYSE:CCGet Rating) by 28.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 254,477 shares of the specialty chemicals company’s stock after buying an additional 56,278 shares during the period. New York State Common Retirement Fund owned about 0.16% of Chemours worth $8,540,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. DekaBank Deutsche Girozentrale lifted its holdings in Chemours by 8.3% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 40,055 shares of the specialty chemicals company’s stock worth $1,328,000 after buying an additional 3,055 shares during the last quarter. Oppenheimer & Co. Inc. lifted its holdings in shares of Chemours by 67.4% in the 4th quarter. Oppenheimer & Co. Inc. now owns 25,308 shares of the specialty chemicals company’s stock worth $849,000 after purchasing an additional 10,192 shares during the last quarter. Fifth Third Bancorp lifted its holdings in shares of Chemours by 12.3% in the 4th quarter. Fifth Third Bancorp now owns 13,820 shares of the specialty chemicals company’s stock worth $464,000 after purchasing an additional 1,514 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Chemours by 15.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,131 shares of the specialty chemicals company’s stock worth $709,000 after purchasing an additional 2,858 shares during the last quarter. Finally, Raymond James Trust N.A. bought a new stake in shares of Chemours in the 4th quarter worth approximately $212,000. 71.63% of the stock is currently owned by institutional investors.

Shares of CC stock opened at $33.73 on Friday. The Chemours Company has a 1 year low of $22.56 and a 1 year high of $38.87. The stock has a market cap of $5.37 billion, a PE ratio of 9.29, a price-to-earnings-growth ratio of 0.58 and a beta of 1.99. The business’s fifty day moving average is $30.09 and its 200-day moving average is $31.47. The company has a debt-to-equity ratio of 3.44, a quick ratio of 1.21 and a current ratio of 1.80.

Chemours (NYSE:CCGet Rating) last issued its earnings results on Thursday, February 10th. The specialty chemicals company reported $0.81 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.87 by ($0.06). The company had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.57 billion. Chemours had a return on equity of 70.34% and a net margin of 9.60%. The business’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.61 earnings per share. Equities research analysts predict that The Chemours Company will post 4.51 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 15th. Investors of record on Friday, February 25th were issued a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 2.96%. The ex-dividend date of this dividend was Thursday, February 24th. Chemours’s payout ratio is 27.55%.

Several analysts recently issued reports on CC shares. StockNews.com started coverage on Chemours in a report on Thursday, March 31st. They issued a “buy” rating on the stock. Zacks Investment Research cut Chemours from a “strong-buy” rating to a “hold” rating and set a $37.00 target price on the stock. in a research report on Wednesday, January 5th. JPMorgan Chase & Co. lowered their target price on Chemours from $35.00 to $30.00 and set a “neutral” rating on the stock in a research report on Monday, February 14th. Royal Bank of Canada lowered their target price on Chemours from $44.00 to $41.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 15th. Finally, UBS Group raised their target price on Chemours from $34.00 to $36.00 and gave the company a “neutral” rating in a research report on Tuesday, January 4th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, Chemours presently has an average rating of “Buy” and a consensus price target of $39.56.

Chemours Company Profile (Get Rating)

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through four segments: Titanium Technologies, Thermal & Specialized Solutions, Advanced Performance Materials, and Chemical Solutions. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure and BaiMax brands for delivering whiteness, brightness, opacity, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

Featured Stories

Institutional Ownership by Quarter for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.